Loomis, Sayles & Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Loomis, Sayles & Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-549,538	Closed	-$20M	–	755
2025 Q2	$20M	Sell	549,538 -11,941	-2%	-$430K	0.03%	244
2025 Q1	$20.3M	Buy	+561,479	New	+$23.4M	0.03%	236
2023 Q4	–	Sell	-152	Closed	-$5K	–	1031
2023 Q3	$5K	Buy	152 +67	+79%	+$2.65K	﹤0.01%	880
2023 Q2	$4K	Buy	+85	New	+$3.94K	﹤0.01%	894
2019 Q4	–	Sell	-238,194	Closed	-$10.2M	–	758
2019 Q3	$10.2M	Buy	238,194 +18,940	+9%	+$1.03M	0.02%	341
2019 Q2	$13.9M	Buy	+219,254	New	+$14M	0.03%	274

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Loomis, Sayles & Company's RARE Position: Q3 2025 in Review

Loomis, Sayles & Company sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 549,538 shares — an estimated $20M sold.

Loomis, Sayles & Company first reported a position in RARE in Q2 2019 and held it in 6 quarters. The position peaked at $20.3M in Q1 2025. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Loomis, Sayles & Company reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Loomis, Sayles & Company sold 549,538 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $20M.
Loomis, Sayles & Company first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and held it in 6 quarters.
Loomis, Sayles & Company's Ultragenyx Pharmaceutical position peaked at $20.3M in Q1 2025.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Loomis, Sayles & Company's 13F filing for Q3 2025, filed 13 Nov 2025.